126 related articles for article (PubMed ID: 18713130)
21. Where are we going with regional therapy for melanoma?
Tyler D
Ann Surg Oncol; 2004 May; 11(5):455-7. PubMed ID: 15078631
[No Abstract] [Full Text] [Related]
22. Clinical trials referral resource.
Wright JJ; Zerivitz K; Gravell A
Oncology (Williston Park); 2005 May; 19(6):722, 725-6, 728 passim. PubMed ID: 15971449
[No Abstract] [Full Text] [Related]
23. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
24. Tumor angiogenesis in melanoma.
Marneros AG
Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595
[TBL] [Abstract][Full Text] [Related]
25. Trends in the treatment and detection of skin cancer.
Emer J; Markowitz O
J Drugs Dermatol; 2011 Jan; 10(1):16-8. PubMed ID: 21197515
[No Abstract] [Full Text] [Related]
26. How melanoma is treated in real life.
Dummer R; Schadendorf D
Arch Dermatol; 2008 May; 144(5):664-5. PubMed ID: 18490596
[No Abstract] [Full Text] [Related]
27. [Working group of Dermatologic Oncology ADO. Second-line therapy in stage IV melanoma].
J Dtsch Dermatol Ges; 2007 Oct; 5(10):959. PubMed ID: 17910683
[No Abstract] [Full Text] [Related]
28. Overcoming melanoma drug resistance through metabolic targeting?
Smalley KS
Pigment Cell Melanoma Res; 2013 Nov; 26(6):793-5. PubMed ID: 24152044
[No Abstract] [Full Text] [Related]
29. Metabolic approaches to treatment of melanoma.
Hersey P; Watts RN; Zhang XD; Hackett J
Clin Cancer Res; 2009 Nov; 15(21):6490-4. PubMed ID: 19861452
[TBL] [Abstract][Full Text] [Related]
30. [Experience with use of mustoforan at the Clinical Oncological Dispensary of the Republic of Tatarstan].
Karpenko LG
Vopr Onkol; 2005; 51(3):388-90. PubMed ID: 16279110
[No Abstract] [Full Text] [Related]
31. Mutated ERBB4: a novel drug target in metastatic melanoma?
Kurppa K; Elenius K
Pigment Cell Melanoma Res; 2009 Dec; 22(6):708-10. PubMed ID: 19735458
[No Abstract] [Full Text] [Related]
32. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
Kirkwood JM; Tarhini AA
J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
[No Abstract] [Full Text] [Related]
33. [Adjuvant interferon therapy in malignant melanoma].
Mohr P
J Dtsch Dermatol Ges; 2007 Jun; 5(6):543-5. PubMed ID: 17537052
[No Abstract] [Full Text] [Related]
34. Hydroxychalcones induce apoptosis in B16-F10 melanoma cells via GSH and ATP depletion.
Navarini AL; Chiaradia LD; Mascarello A; Fritzen M; Nunes RJ; Yunes RA; Creczynski-Pasa TB
Eur J Med Chem; 2009 Apr; 44(4):1630-7. PubMed ID: 19211173
[TBL] [Abstract][Full Text] [Related]
35. Editorial: melanomas and Wnts.
Goding C
Pigment Cell Res; 2005 Jun; 18(3):149. PubMed ID: 15892710
[No Abstract] [Full Text] [Related]
36. Measurement of matrix metalloproteinases in serum of patients with melanoma: snarled in technical pitfalls.
Zucker S; Cao J
Clin Cancer Res; 2005 Jul; 11(14):5069-70. PubMed ID: 16033818
[No Abstract] [Full Text] [Related]
37. Metabolic features of melanoma: a gold mine of new therapeutic targets?
Marchetti P; Guerreschi P; Kluza J; Mortier L
Curr Cancer Drug Targets; 2014; 14(4):357-70. PubMed ID: 24720363
[TBL] [Abstract][Full Text] [Related]
38. Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence.
Grillo E; Corsini M; Ravelli C; Zammataro L; Bacci M; Morandi A; Monti E; Presta M; Mitola S
Cancer Lett; 2021 Jun; 507():80-88. PubMed ID: 33744390
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
Kelley RK; Venook AP
J Clin Oncol; 2008 Dec; 26(36):5845-8. PubMed ID: 19029408
[No Abstract] [Full Text] [Related]
40. Novel therapeutics for melanoma.
Seetharamu N; Ott PA; Pavlick AC
Expert Rev Anticancer Ther; 2009 Jun; 9(6):839-49. PubMed ID: 19496721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
